Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug restores blood pressure faster in children with septic shock?

NCT ID NCT07775001

Disease control Sponsor: Nishtar Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial compares two emergency medications, dopamine and epinephrine, to see which one is better at reversing septic shock in children aged 2 to 12. Septic shock is a life-threatening condition where infection causes dangerously low blood pressure. The study randomly assigns children who haven't improved with fluids to receive either drug, then checks if blood pressure and other signs of shock improve within the first hour. The goal is to find out if one drug works faster and more effectively, which could guide emergency treatment for children worldwide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
epinephrine and dopamine
What this could lead to
If epinephrine works better, it could become the preferred first-line treatment for children with septic shock, potentially saving more lives.
What could go wrong
This is a small, early-stage trial, so results may not apply to all children. Both drugs have risks like abnormal heart rhythms, and the study doesn't guarantee long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

66 people

The number who actually took part.

Started

Feb 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 2 to 12 years, of either sex, presenting to the Pediatric Emergency Department or Pediatric Intensive Care Unit. * Suspected or proven infection, supported by a documented clinical focus of infection or microbiological evidence. * Fluid-refractory hypotensive septic shock . Exclusion Criteria: * Shock not meeting the operational definition of fluid-refractory hypotensive septic shock after standardized fluid resuscitation. * Receipt of any vasoactive infusion, including dopamine, epinephrine, norepinephrine, vasopressin, dobutamine, or equivalent, before eligibility confirmation and randomization. * Known cyanotic congenital heart disease, significant structural heart disease with hemodynamic compromise, or documented cardiomyopathy. * Primary arrhythmic instability requiring antiarrhythmic therapy at presentation. * Anaphylaxis, acute hemorrhage, major trauma, or obstructive shock, such as tension pneumothorax or cardiac tamponade, as the primary cause of hypotension. * Clinical indication for an alternative initial vasoactive strategy mandated by the treating team at screening, including predominant warm vasodilatory shock requiring norepinephrine as first-line therapy. * Documented limitation of care orders, including do-not-resuscitate status, or anticipated withdrawal of life-sustaining therapy at presentation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Septic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock

Contacts and locations

Locations

  • Nishtar Hospital Multan

    Multan, Punjab Province, 66000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.